Urocure SR is specifically indicated for the treatment & prophylaxis of urinary tract infections caused by susceptible strains of Escherichia coli, Enterococci, Staphylococcus aureus, Staphylococcus saprophyticus and certain susceptible strains of Klebsiella and Enterobacter species.
Urocure SR is specifically indicated for the treatment & prophylaxis of urinary tract infections caused by susceptible strains of Escherichia coli, Enterococci, Staphylococcus aureus, Staphylococcus saprophyticus and certain susceptible strains of Klebsiella and Enterobacter species.
50 mg capsule: Each capsule contains Nitrofurantoin (as macrocrystal) USP 50 mg.
100 mg capsule: Each capsule contains Nitrofurantoin (as macrocrystal) USP 100 mg.
Oral suspension: Each 5 ml suspension contains Nitrofurantoin Monohydrate USP equivalent to Nitrofurantoin 25mg.
Nitrofurantoin is an antibacterial agent specific for urinary tract infections. Nitrofurantoin is highly soluble in urine, to which it may impart a brown color. Nitrofurantoin inactivates or alters bacterial ribosomal proteins and other macromolecules.
Antacids containing Magnesium Trisilicate, when administered concomitantly with Urocure SR, reduce both the rate and extent of absorption of Uricosuric drugs, such as Probenecid and Sulfinpyrazone, can inhibit renal tubular secretion of Urocure SR.
Anuria, oliguria or significant impairment of renal function are contraindications. This drug is contraindicated in pregnant patients at 38-42 weeks, during labor and delivery. Nitrofurantoin is also contraindicated in those patients with known hypersensitivity to Nitrofurantoin.
The most frequent clinical adverse events are nausea, headache, and flatulence. Other less occurred adverse events are diarrhea, dyspepsia, abdominal pain, constipation, emesis, dizziness and drowsiness.
Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed.
If acute, sub-acute or chronic pulmonary reactions occur, Urocure SR should be discontinued. Antacid preparations containing magnesium trisilicate should not be taken while taking Urocure SR.
Occasional incidents of acute overdosage of Urocure SR have not resulted in any specific symptoms other than vomiting. Induction of emesis is recommended.
Systemic Urinary Anti- infective
Do not store above 30°C. Keep away from light and out of the reach of children.
